NYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $13.65 -0.24 (-1.72%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biohaven Stock (NYSE:BHVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biohaven alerts:Sign Up Key Stats Today's Range$13.50▼$14.3750-Day Range$12.03▼$17.1252-Week Range$7.48▼$18.57Volume3.12 million shsAverage Volume2.70 million shsMarket Capitalization$2.06 billionP/E RatioN/ADividend YieldN/APrice Target$18.69Consensus RatingModerate Buy Company Overview Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options. Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases. Its programs have included novel potassium-channel modulators, glutamate pathway therapies, brain-penetrant immune-targeting medicines and other therapies designed to act on neurological or immunological mechanisms. The company traces its origins to Biohaven Pharmaceutical, which was founded in 2013. In 2022, Pfizer acquired Biohaven’s commercial and late-stage calcitonin gene-related peptide portfolio, including the migraine products Nurtec ODT and Zavzpret, while the remaining research and development operations continued as the current Biohaven Ltd. Biohaven is headquartered in New Haven, Connecticut, and its programs are advanced through clinical development and regulatory processes in the United States and other international markets. Vlad Coric serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Biohaven Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 57% of companies evaluated by MarketBeat, and ranked 402nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBiohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 2 strong buy ratings, 8 buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialBiohaven has a consensus price target of $18.69, representing about 34.8% upside from its current price of $13.86.Amount of Analyst CoverageBiohaven has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($3.33) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 35.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.59% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 4.78.Change versus previous monthShort interest in Biohaven has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentBiohaven has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Biohaven this week, compared to 5 articles on an average week.Search Interest7 people have searched for BHVN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BHVN Stock News HeadlinesBiohaven's Kv7 Program Remains Key Stock Driver, UBS Says22 minutes ago | marketscreener.comMBiohaven Rated Buy on Opakalim’s KV7 Safety Edge and Differentiated Tolerability ProfileSeptember 18 at 7:31 AM | tipranks.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 18 at 1:00 AM | Paradigm Press (Ad)Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 13, 2026 | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for Biohaven (NYSE:BHVN)September 12, 2026 | americanbankingnews.comBiohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)September 11, 2026 | prnewswire.comBiohaven Shares Fall Premarket on Partial FDA Hold on BHV-7000September 11, 2026 | marketscreener.comMBiohaven Shares Drop 15% On FDA Partial Clinical Hold DecisionSeptember 10, 2026 | rttnews.comSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $11.26 at the start of the year. Since then, BHVN stock has increased by 23.1% and is now trading at $13.86. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.15. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Top institutional investors of Biohaven include BlackRock Inc. (8.77%), Jupiter Topco LLC (5.68%), Bank of America Corp DE (0.98%) and 5AM Venture Management LLC (0.49%). Insiders that own company stock include John W Childs, Gregory Bailey, Vlad Coric, Matthew Buten, George C Clark and Irina Antonijevic. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/10/2026Today9/18/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BHVN's financial health is in the Green zone, according to TradeSmith. BHVN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CIK1935979 Webwww.biohaven.com Phone203-404-0410FaxN/AEmployees274Year Founded2014Price Target and Rating Average Price Target for Biohaven$18.69 High Price Target$42.00 Low Price Target$9.00 Potential Upside/Downside+36.9%Consensus RatingModerate Buy Rating Score (0-4)2.59 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$738.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,328.94% Return on Assets-138.27% Debt Debt-to-Equity Ratio21.23 Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book35.00Miscellaneous Outstanding Shares151,040,000Free Float130,200,000Market Cap$2.06 billion OptionableOptionable Beta1.28 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSE:BHVN) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
